Clinical trials: Renal Insufficiency
Bladder Transitional Cell Carcinoma Stage IV
JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin
This study is assessing the combination of well known cytotoxics with a novel anti-cancer agent that could be administered as monotherapy without renal toxicity in patients with renal impairment presenting with advanced or…
- Trial name
- JASINT1 (NCT01599013)
- Testing
- Vinflunine, Gemcitabine, Vinflunine, Carboplatin
- Where
- France
- Volunteers
- 69 people
- Sponsor
- Pierre Fabre Medicament
Acute Kidney Injury, Acute Kidney Injury Due to Sepsis
QUELIMMUNE (SCD-PED) PediAtric SurVeillance REgistry
QUELIMMUNE is FDA-approved under an HDE for the treatment of pediatric patients (weight ≥10kg and age ≤22 years) with AKI due to sepsis or a septic condition on antibiotic therapy and requiring RRT.
- Trial name
- SAVE (NCT06517810)
- Testing
- QUELIMMUNE (SCD-PED)
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- SeaStar Medical
End Stage Renal Disease
Safety and Effects of Supplementation With Ergocalciferol on Erythropoietin Dosing in Hemodialysis Patients
A few studies have reported erythropoiesis-stimulating agent (ESA) doses before and after 25D supplementation, but only one of these is a prospective clinical trial, and it is a small, single center study lacking a control arm.
- Trial name
- NCT01395823
- Testing
- ergocalciferol supplementation
- Where
- 12 sites in United States
- Volunteers
- 470 people
- Sponsor
- Dialysis Clinic, Inc.
Chronic Renal Failure
A Trial to Investigate the Efficacy and Safety of Orally Administered Tolvaptan (OPC-41061) in Patients With Chronic Renal Failure Undergoing Hemodialysis or Hemodiafiltration
This is a study to investigate the efficacy and safety of OPC-41061 by 24-week oral administration of OPC-41061 at 15-mg or 30-mg or placebo in patients with chronic renal failure who are undergoing hemodialysis or…
- Trial name
- NCT02331680
- Testing
- OPC-41061
- Where
- 4 sites in Japan
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Renal Insufficiency
Tetraspan 6 Percent (%) Combined With Sterofundin ISO Versus Albumin 5 Percent (%) Combined With Sodium Chloride (NaCL)
This investigational study will investigate two different volume replacement regimes in patients suffering from compromised renal function.
- Trial name
- NCT00936247
- Testing
- HES 130/0.42 + electrolyte solution, Albumin + electrolyte solution
- Where
- 2 sites in Germany
- Volunteers
- 2 people
- Sponsor
- B. Braun Melsungen AG
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus, Renal Impairment
Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment
This Phase 1 study is intended to assess the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability of LX4211 following once daily oral administration in subjects with type 2 diabetes mellitus (T2DM) and moderate…
- Trial name
- NCT01555008
- Testing
- LX4211
- Where
- 6 sites in United States
- Volunteers
- 31 people
- Sponsor
- Lexicon Pharmaceuticals
Kidney Failure, Chronic
Comparing Absorption of Dietary Phosphorus When Administering FOSRENOL® or RENVELA® in Healthy Adult Volunteers
The purpose of this study is to compare the absorption of dietary phosphorus following a single dose with lanthanum carbonate (1000mg) and a single dose of sevelamer carbonate (2400mg).
- Trial name
- NCT00875017
- Testing
- Lanthanum Carbonate, Sevelamer
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Shire
Chronic Kidney Diseases, Acute Kidney Injury
Nova Max Creatinine and eGFR Meter System
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the…
- Trial name
- NCT05118074
- Testing
- Creatinine, eGFR
- Where
- 3 sites in United States
- Volunteers
- 360 people
- Sponsor
- Nova Biomedical
Renal Impairment
Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal Impairment
Primary Objective: To study the effect of mild, moderate and severe renal impairment on the pharmacokinetics of SAR302503. Secondary Objective: To assess the tolerability of SAR302503 given as a single 300 mg dose in subjects…
- Trial name
- NCT01763190
- Testing
- SAR302503
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Central Venous Pressure
Comparison of a Non-Invasive Central Venous Pressure Device and Physical Examination in Patients With Chronic Kidney Disease
The primary objective of this study is to determine whether a correlation exists between the Mespere Non-Invasive Central Venous Pressure (NICVP) device for measuring central venous pressure (CVP), and assessment of CVP via…
- Trial name
- NCT01243515
- Testing
- Non-Invasive Central Venous Pressure monitor, Physical examination of jugular vein
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mespere Lifesciences Inc.
Contrast-induced Nephropathy, Chronic Kidney Diseases
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
Multi-center randomized trial to assess the safety and performance of low-frequency therapeutic ultrasound for maintaining renal function after contrast exposure.
- Trial name
- LOTUS (NCT04877847)
- Testing
- Low-frequency therapeutic ultrasound (LOTUS), LOTUS System with Ultrasound Disabled
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Sonogenix
Renal Insufficiency
SP2086 Pharmacokinetic Study in Renal Insufficiency Patients
The purpose of the study is to investigate the SP2086 pharmacokinetic in Renal Insufficiency Patients.
- Trial name
- NCT02815774
- Testing
- SP2086
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
IgA Nephropathy
A Study to Determine if BHV-1400 is Effective and Safe in Adults With IgA Nephropathy
The purpose of this study is to determine if BHV-1400 is effective and safe in the treatment of IgA Nephropathy. Participants will be randomized in a 2:1 ratio to receive either BHV-1400 or placebo.
- Trial name
- NCT07642050
- Testing
- BHV-1400
- Volunteers
- 420 people
- Sponsor
- Biohaven Therapeutics Ltd.
Chronic Kidney Disease(CKD), Progression, Disease
Validation of a Proteomic Biomarker to Predict Progression of Chronic Kidney Disease
The goal of this longitudinal observational study is to estimate the performances of a candidate proteomic biomarker to identify patients at short term risk of chronic kidney disease (CKD) progression, in CKD patients attending…
- Trial name
- KidneySign (NCT06962891)
- Testing
- CKD progression biomarker
- Where
- 3 sites in Austria, France and 1 more
- Volunteers
- 213 people
- Sponsor
- Angel Argiles
Chronic Kidney Disease
A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
This research study is designed to assess the safety and effectiveness of an experimental drug called vonapanitase (PRT-201) in patients both receiving or expecting to receive hemodialysis who have chronic kidney disease and who…
- Trial name
- NCT02414841
- Testing
- Vonapanitase
- Where
- 41 sites in United States, Canada
- Volunteers
- 696 people
- Sponsor
- Proteon Therapeutics
Schizophrenia, Psychiatric Disorders
Trial Evaluating OPC-34712 in Subjects With Normal Renal Function and Renally Impaired Subjects
This trial is an open-label, multi-center, parallel-arm, single-dose trial in 2 groups: 1 group of subjects with normal renal function and 1 group of severely renally impaired subjects.
- Trial name
- NCT01289080
- Testing
- OPC-34712
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Chronic Kidney Disease
Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
The main purpose of this study is to investigate the efficacy and safety of Volenrelaxin in adults with Chronic Kidney Disease. The study will last about 24 weeks.
- Trial name
- NCT06598631
- Testing
- Volenrelaxin
- Where
- 35 sites in United States, Australia and 3 more
- Sponsor
- Eli Lilly and Company
Chronic Renal Failure, Anemia
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
The purpose of this study is to evaluate the safety and efficacy of multiple intravenous doses of pegol-Sihematide in participants with chronic kidney disease (CKD) who are on dialysis.
- Conditions
- Chronic Renal Failure, Anemia, Dialysis
- Trial name
- NCT02586402
- Testing
- pegol-Sihematide, Epoetin Alfa
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Diabetic Kidney Disease (DKD)
Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
This study is researching an experimental drug called ALN-ANG3 (called "study drug"). The study is focused on participants who have diabetic kidney disease.
- Trial name
- ANCHOR-POC (NCT07271186)
- Testing
- ALN-ANG3, Evinacumab
- Where
- 59 sites in United States
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.